Multiple Myeloma Research Consortium

Extended Daratumumab-KRd Therapy Achieves 85% Three-Year PFS in Newly Diagnosed Multiple Myeloma Without Transplant

- A phase II trial of extended daratumumab-carfilzomib-lenalidomide-dexamethasone (Dara-KRd) for 24 cycles achieved 75% stringent complete response and/or minimal residual disease negativity in newly diagnosed multiple myeloma patients. - The treatment demonstrated an impressive 85% three-year progression-free survival rate without autologous stem cell transplant, including 100% for standard-risk patients and 92% for those with one high-risk cytogenetic abnormality. - Extended quadruplet therapy showed deepening responses over time, with minimal residual disease negativity rates increasing from 35% after 8 cycles to 53% as best response, suggesting potential to defer transplant in select patients.